Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	224.55	269.57	519.27	1,323	286.93
Short-Term Investments	1.2	7.3	148.42	16.12	-
Cash & Short-Term Investments	225.75	276.87	667.69	1,339	286.93
Cash Growth	-18.46%	-58.53%	-50.15%	366.84%	-1.45%
Accounts Receivable	130.88	140.74	58.53	81.32	320.84
Other Receivables	8.12	7.73	4.69	3.09	11.33
Receivables	139	148.47	63.22	84.41	332.17
Inventory	132.89	64.94	112.33	246.72	173.3
Prepaid Expenses	57.49	71.45	83.25	103.22	89.28
Other Current Assets	220.9	174.66	171.53	149.95	15.73
Total Current Assets	776.02	736.38	1,098	1,924	897.41
Property, Plant & Equipment	1,577	1,705	1,847	1,978	1,351
Long-Term Investments	155.56	177.87	190.81	199.51	109.59
Goodwill	-	23.92	23.92	23.92	23.92
Other Intangible Assets	41.12	12.34	18.98	25.93	33.71
Long-Term Deferred Tax Assets	101.06	98.6	95.49	89.72	81.11
Other Long-Term Assets	610.8	614.67	495.85	211.93	642.46
Total Assets	3,261	3,368	3,770	4,453	3,139
Accounts Payable	77.47	34.63	44.05	52.52	54.68
Accrued Expenses	-	98.05	112.32	104.21	96.4
Short-Term Debt	280	-	-	100	50
Current Portion of Long-Term Debt	198.29	168.08	125.92	105.88	15.6
Current Portion of Leases	39.21	31.92	30.57	37.28	28.59
Current Unearned Revenue	361.69	230.85	187.28	142.28	152.12
Other Current Liabilities	149.41	97.97	253.28	92.57	142.69
Total Current Liabilities	1,106	661.5	753.42	634.73	540.07
Long-Term Debt	433.67	611.37	530.4	656.32	474.4
Long-Term Leases	122.46	72.04	39.39	56.37	176.06
Long-Term Deferred Tax Liabilities	-	-	-	-	3.75
Other Long-Term Liabilities	-	-	-	-	38.07
Total Liabilities	1,662	1,345	1,323	1,347	1,232
Common Stock	2,072	2,070	2,059	2,053	1,533
Additional Paid-In Capital	67.32	421.11	1,074	1,468	576.95
Retained Earnings	-540.63	-466.91	-682.64	-406.83	-254.34
Comprehensive Income & Other	0.04	-0.79	-3.32	-8.8	50.72
Shareholders' Equity	1,599	2,023	2,447	3,106	1,907
Total Liabilities & Equity	3,261	3,368	3,770	4,453	3,139
Total Debt	1,074	883.39	726.28	955.85	744.64
Net Cash (Debt)	-847.89	-606.53	-58.59	383.63	-457.72
Net Cash Per Share	-4.10	-2.94	-0.29	2.32	-3.08
Filing Date Shares Outstanding	205.66	207.01	205.89	205.31	153.33
Total Common Shares Outstanding	205.66	207.01	205.89	205.31	153.33
Working Capital	-330.04	74.89	344.59	1,289	357.34
Book Value Per Share	7.78	9.77	11.89	15.13	12.43
Tangible Book Value	1,558	1,987	2,404	3,056	1,849
Tangible Book Value Per Share	7.58	9.60	11.68	14.88	12.06
Buildings	-	792.86	792.86	791.68	-
Machinery	-	1,594	1,603	1,575	837.57
Construction In Progress	-	158.09	106.85	3.35	624.35
Leasehold Improvements	-	325.53	317.34	307.77	276.23

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.